Bleomycin

Product manufactured by Hospira, Inc.

Application Nr Approved Date Route Status External Links
ANDA065031 None Intramuscular None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Bleomycin For Injection Should Be Considered A Palliative Treatment. It Has Been Shown To Be Useful In The Management Of The Following Neoplasms Either As A Single Agent Or In Proven Combinations With Other Approved Chemotherapeutic Agents: Squamous Cell Carcinoma Head And Neck (Including Mouth, Tongue, Tonsil, Nasopharynx, Oropharynx, Sinus, Palate, Lip, Buccal Mucosa, Gingivae, Epiglottis, Skin, Larynx), Penis, Cervix, And Vulva. The Response To Bleomycin Is Poorer In Patients With Previously Irradiated Head And Neck Cancer. Lymphomas Hodgkin's Disease, Non-Hodgkin's Lymphoma. Testicular Carcinoma Embryonal Cell, Choriocarcinoma, And Teratocarcinoma. Bleomycin Has Also Been Shown To Be Useful In The Management Of: Malignant Pleural Effusion Bleomycin Is Effective As A Sclerosing Agent For The Treatment Of Malignant Pleural Effusion And Prevention Of Recurrent Pleural Effusions.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Bleomycin Sulfate

Comments